OMER · Omeros Corporation
Is OMER setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Omeros Corporation, in one place.
Today's breakout radarIs OMER setting up for a breakout?
Breakout Radar API →Not today. OMER is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about OMER?
Stock Sentiment API →Bulls: A post argues that if Omeros' third-quarter results come anywhere close to its second-quarter results, the stock will hit $30 this year.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about OMER?
News Sentiment API →No recent news reading for OMER. The News Sentiment API reads today's headlines on any US stock.
Are OMER insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Borges David J.$210K · Sep 23, 2026
- Sold · Borges David J.$210K · Sep 22, 2026
- Sold · Cancelmo Peter B$464K · Aug 31, 2026
- Sold · Cancelmo Peter B$466K · Aug 28, 2026
- Sold · HANISH ARNOLD C$95K · Aug 27, 2026
How is Omeros Corporation's business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $28.5M | — | $13.2M | $0.15 |
| Mar 31, 2026 | $9.9M | — | $56.1M | $0.62 |
| Jun 30, 2025 | $0 | — | −$25.4M | $-0.43 |
| Mar 31, 2025 | $0 | — | −$33.5M | $-0.58 |
From the company's SEC filings (10-Q and 10-K).
What does Omeros Corporation expect?
Company Guidance API →- 2025 · pdufa date for fda action on narsoplimab bla · 8-K filed Mar 31, 2025
“We expect the target date for FDA action under the Prescription Drug User Fee Act (“PDUFA”) to be six months following the date of resubmission to FDA, meaning, in this case, the PDUFA date would be in September 2025.”
- first half of 2025 · submission of european marketing authorization application (maa) for narsoplimab in ta-tma · 8-K filed Mar 31, 2025
“We expect to submit our European marketing authorization application (“MAA”) for narsoplimab in TA-TMA in the first half of 2025.”
- late next year · phase 3 zaltenibart pnh program data readout · 8-K filed Mar 31, 2025
“Zaltenibart’s compelling results in our Phase 2 PNH trials are highly predictive of the similarly designed and ongoing Phase 3 program in PNH, which remains on track to readout data late next year”
- later this year · data from nida-funded oms527 trial in patients with cocaine use disorder · 8-K filed Mar 31, 2025
“Also later this year, we expect data from our NIDA-funded OMS527 trial in patients with cocaine use disorder.”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.